What Does BCR-ABL Mean on a Report?

BCR::ABL1 is not a gene you were born with. It is a hybrid gene created when two chromosomes swap pieces.

The ABL1 gene sits on the long arm of chromosome 9. The BCR gene sits on the long arm of chromosome 22. In this swap, the two ends join, and the fused BCR::ABL1 gene forms. The shortened chromosome 22 that results is called the Philadelphia chromosome, after the city where it was described.

The fusion gene makes a protein that behaves like an accelerator jammed down. Normal ABL1 is a tyrosine kinase, an enzyme that adds phosphate groups to signal cell division. Normal ABL1 turns off when it should. BCR::ABL1 does not. The cell keeps dividing.

Note the punctuation. Modern reports use BCR::ABL1 with two colons, the current convention for a fusion. Older reports write BCR-ABL or bcr/abl. They mean the same thing.

BCR::ABL1 defines chronic myeloid leukemia. It is also found in a subset of acute lymphoblastic leukemia, where it is called Philadelphia chromosome-positive ALL and carries a different treatment plan.

CML is uncommon. The American Cancer Society projects 9,650 new US cases and 1,170 deaths for 2026, figures NCI posts on its SEER Stat Facts page. NCI's own measurements put the median age at diagnosis at 67 and five-year relative survival at 71.1 percent for cases diagnosed from 2016 through 2022, a figure that pools all ages, including years before the newest drugs.

CML was the first cancer with a drug aimed at its specific molecular fault. Tyrosine kinase inhibitors (TKIs) block the BCR::ABL1 enzyme.

Current first-line options for newly diagnosed chronic-phase CML include imatinib, nilotinib, dasatinib, bosutinib, and asciminib. With any of them, 10-year event-free survival and overall survival exceed 90 percent.

Asciminib works differently from the others. It binds a pocket on the ABL1 protein called the myristoyl pocket, a site the older drugs do not use. In a trial of 405 newly diagnosed patients, the major molecular response rate at 48 weeks was 67.7 percent with asciminib and 49 percent with imatinib, nilotinib, dasatinib, or bosutinib. Grade 3 or worse side effects occurred in 38 percent on asciminib, 44 percent on imatinib, and 55 percent on the other TKIs. Stopping because of side effects happened in 5 percent on asciminib, 11 percent on imatinib, and 10 percent on the others.

The PDQ raises a point most patient pages skip. In 2024 asciminib cost about $260,000 a year. Imatinib cost about $500 a year. That gap is a legitimate part of the conversation, not a rude question, and it is worth asking your team and your insurer about directly.

BCR::ABL1 is monitored by a blood test that measures how much of the fusion transcript is present, reported as a percentage on the International Scale. The response categories have precise definitions:

• EMR, early molecular response: BCR::ABL1 at 10 percent or less at 3 months. That is more than a 1-log reduction.
• MMR, major molecular response: BCR::ABL1 at 0.1 percent or less. That is more than a 3-log reduction.
• DMR, deep molecular response, also called MR4: BCR::ABL1 at 0.01 percent or less.
• MR4.5: 0.0032 percent or less.
• MR5: 0.001 percent or less.

Two milestones matter most. At 3 months, an EMR is linked to the best failure-free, progression-free, and overall survival. After 1 year, the preferred target is MMR, and the optimal target is a deep molecular response.

A single number at 3 months does not decide everything, and the PDQ is unusually frank about this.

Some people whose BCR::ABL1 is above 10 percent at 3 months still do well, provided the level is falling fast. In a retrospective analysis, those with a halving time under 76 days did well despite missing the 10 percent mark.

And forcing a change of drug based on the 10 percent level at 3 to 6 months is described as problematic, because roughly 75 percent of people with a suboptimal response at that point still do well.

So if you are told your 3-month number is above 10 percent, two follow-up questions are reasonable. How fast is it falling compared with my baseline? And is switching drugs the only option, or is watching the trend for another 3 months also defensible?

CML runs in phases. Chronic phase is where most people are diagnosed and where the drugs work best. In accelerated phase, the cells still mature but look increasingly abnormal. Blast crisis brings fever, an enlarged spleen, and more than 20 percent blasts in the blood.

Historically the rate of moving from chronic phase to blast crisis was 5 to 10 percent in the first 2 years and 20 percent in subsequent years. Modern TKIs have changed that picture substantially, but it is the reason molecular monitoring continues even when you feel entirely well.

These are pills taken every day, often for years, and adherence is genuinely the variable most under your control. Missing doses shows up in the numbers.

Ask about food rules, because they differ by drug and are not interchangeable. Ask which of your other medicines and supplements interact. Grapefruit and St John's wort affect the liver enzymes that handle several of these drugs.

• New or worsening breathlessness, ankle swelling, or sudden weight gain.
• Chest pain, or leg pain and swelling on one side.
• Fever of 100.4 F (38 C) or higher, or shaking chills.
• Severe or persistent diarrhea, or vomiting that stops you taking the pill.
• Bruising without injury, tiny red skin dots, or bleeding that will not stop.
• Left upper abdominal pain or early fullness, which can mean an enlarging spleen.

Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia Phases, What Does a FISH Test Mean in Cancer?, and Targeted Therapy.

• https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq
• https://seer.cancer.gov/statfacts/html/cmyl.html